GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Tandem Diabetes Care Inc (NAS:TNDM) » Definitions » Cash Flow from Investing

Tandem Diabetes Care (Tandem Diabetes Care) Cash Flow from Investing : $-85.7 Mil (TTM As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Tandem Diabetes Care Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Dec. 2023, Tandem Diabetes Care spent $5.2 Mil on purchasing property, plant, equipment. It gained $0.0 Mil from selling property, plant, and equipment. It spent $0.0 Mil on purchasing business. It gained $0.0 Mil from selling business. It spent $119.8 Mil on purchasing investments. It gained $130.7 Mil from selling investments. It paid $0.0Mil for net Intangibles purchase and sale. And it paid $22.3 Mil for other investing activities. In all, Tandem Diabetes Care spent $16.6 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Dec. 2023.


Tandem Diabetes Care Cash Flow from Investing Historical Data

The historical data trend for Tandem Diabetes Care's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tandem Diabetes Care Cash Flow from Investing Chart

Tandem Diabetes Care Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -56.96 -296.06 -186.88 33.17 -85.74

Tandem Diabetes Care Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 35.78 -26.33 5.70 -48.53 -16.58

Tandem Diabetes Care Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Tandem Diabetes Care's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:

Tandem Diabetes Care's Cash Flow from Investing for the quarter that ended in Dec. 2023 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-85.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tandem Diabetes Care  (NAS:TNDM) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Tandem Diabetes Care's purchase of property, plant, equipment for the three months ended in Dec. 2023 was $-5.2 Mil. It means Tandem Diabetes Care spent $5.2 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Tandem Diabetes Care's sale of property, plant, equipment for the three months ended in Dec. 2023 was $0.0 Mil. It means Tandem Diabetes Care gained $0.0 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Tandem Diabetes Care's purchase of business for the three months ended in Dec. 2023 was $0.0 Mil. It means Tandem Diabetes Care spent $0.0 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Tandem Diabetes Care's sale of business for the three months ended in Dec. 2023 was $0.0 Mil. It means Tandem Diabetes Care gained $0.0 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Tandem Diabetes Care's purchase of investment for the three months ended in Dec. 2023 was $-119.8 Mil. It means Tandem Diabetes Care spent {stock_data.stock.currency_symbol}}119.8 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Tandem Diabetes Care's sale of investment for the three months ended in Dec. 2023 was $130.7 Mil. It means Tandem Diabetes Care gained $130.7 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Tandem Diabetes Care's net Intangibles purchase and sale for the three months ended in Dec. 2023 was $0.0 Mil. It means Tandem Diabetes Care paid $0.0 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Tandem Diabetes Care's cash from discontinued investing activities for the three months ended in Dec. 2023 was 0.0 Mil. It means Tandem Diabetes Care paid $0.0 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Tandem Diabetes Care's cash from other investing activities for the three months ended in Dec. 2023 was $-22.3 Mil. It means Tandem Diabetes Care paid $22.3 Mil for other investing activities.


Tandem Diabetes Care Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Tandem Diabetes Care's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Tandem Diabetes Care (Tandem Diabetes Care) Business Description

Traded in Other Exchanges
Address
11075 Roselle Street, San Diego, CA, USA, 92121
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. Nearly three quarters of total revenue is derived from the U.S., with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.
Executives
Dick Allen director 11045 ROSELLE STREET, SAN DIEGO CA 92121
Shannon Marie Hansen officer: SVP & General Counsel C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121
Leigh Vosseller officer: Senior Vice President and CFO C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121
Kathleen Mcgroddy-goetz director C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121
Peyton R Howell director C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121
David B Berger officer: GENERAL COUNSEL 11045 ROSELLE STREET, SAN DIEGO CA 92121
Malagueira Joao Paulo Falcao director C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121
Myoungil Cha director C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121
Kim D Blickenstaff director, officer: PRESIDENT AND CEO C/O MEDIVATION, INC., 201 SPEAR STREET, 3RD FLOOR, SAN FRANCISCO CA 94105
John F Sheridan officer: EXECUTIVE VP AND COO C/O TANDEM DIABETES CARE, INC., 11045 ROSELLE STREET, SAN DIEGO CA 92121
Christopher J Twomey director 4767 NEXUS CENTRE DRIVE, SAN DIEGO CA 92121
Rebecca B Robertson director ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
James Leal officer: SVP, Operations C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121
Elizabeth Anne Gasser officer: EVP, Chief Strategy Officer C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121
Susan Morrison officer: CAO 11045 ROSELLE STREET, SAN DIEGO CA 92121

Tandem Diabetes Care (Tandem Diabetes Care) Headlines